Salute e Benessere
Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations
CASTRES, France , Oct. 24, 2024 /PRNewswire/ -- Pierre Fabre Laboratories announced today that the first patient has been dosed with PFL-002/VERT-002, a monoclonal antibody acting as a degrader of c-MET, in a phase I/II first-in-human dose-escalation, dose-optimization and dose-expansion trial, for patients with Non-Small Cell Lung Cancer (NSCLC) harbouring MET alterations.
The PFL-002/VERT-002 phase I/II trial is an open label, multi-centre study that aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of PFL-002/VERT-002, as a monotherapy for patients with MET-dependent tumors, including those emerging with acquired resistance to other treatments.
Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for approximately 85% of newly diagnosed lung cancer cases, and MET, also known as hepatocyte growth factor receptor (HGFR), is an oncogene driver in subsets of patients suffering from NSCLC. MET exon 14 skipping mutation and MET amplification are found as primary oncogenic drivers and MET amplification as a resistance mechanism to selected targeted therapies.
said
Contact: laure.sgandurra@pierre-fabre.com
PDF -
https://mma.prnewswire.com/media/2538658/Pierre_Fabre_PFL_002_Vert_002.pdf
View original content to download multimedia: https://www.prnewswire.co.uk/news-releases/pierre-fabre-announce-1st-patient-dosed-in-phase-iii-of-pfl-002vert-002-a-targeted-therapy-in-nsclc-with-met-alterations-302284851.html